Porous silicon and silica carriers for delivery of peptide therapeutics
Open Access
- 31 May 2024
- journal article
- research article
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (12) , 3549-3567
Abstract
Peptides have gained tremendous popularity as biological therapeutic agents in recent years due to their favourable specificity, diversity of targets, well-established screening methods, ease of production, and lower cost. However, their poor physiological and storage stability, pharmacokinetics, and fast clearance have limited their clinical translation. Novel nanocarrier-based strategies have shown promise in overcoming these issues. In this direction, porous silicon (pSi) and mesoporous silica nanoparticles (MSNs) have been widely explored as potential carriers for the delivery of peptide therapeutics. These materials possess several advantages, including large surface areas, tunable pore sizes, and adjustable pore architectures, which make them attractive carriers for peptide delivery systems. In this review, we cover pSi and MSNs as drug carriers focusing on their use in peptide delivery. The review provides a brief overview of their fabrication, surface modification, and interesting properties that make them ideal peptide drug carriers. The review provides a systematic account of various studies that have utilised these unique porous carriers for peptide delivery describing significant in vitro and in vivo results. We have also provided a critical comparison of the two carriers in terms of their physicochemical properties and short-term and long-term biocompatibility. Lastly, we have concluded the review with our opinion of this field and identified key areas for future research for clinical translation of pSi and MSN-based peptide therapeutic formulations. Graphical abstractKeywords
All Related Versions
Funding Information
- University of New South Wales
- University of New South Wales
This publication has 150 references indexed in Scilit:
- Synthesis and Functionalization of a Mesoporous Silica Nanoparticle Based on the Sol–Gel Process and Applications in Controlled ReleaseAccounts of Chemical Research, 2007
- A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device—a first-in-man studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Dissociation of Lung Function Changes with Humoral Immunity during Inhaled Human Insulin TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Antibody Response to Inhaled Insulin in Patients with Type 1 or Type 2 Diabetes. An Analysis of Initial Phase II and III Inhaled Insulin (Exubera) Trials and a Two-Year Extension TrialThe Journal of Clinical Endocrinology & Metabolism, 2005
- Engineering the Chemistry and Nanostructure of Porous Silicon Fabry-Pérot Films for Loading and Release of a SteroidLangmuir, 2004
- Microfabricated Porous Silicon Particles Enhance Paracellular Delivery of Insulin Across Intestinal Caco-2 Cell MonolayersPharmaceutical Research, 2003
- Expression in Escherichia coli of chemically synthesized genes for human insulin.Proceedings of the National Academy of Sciences, 1979
- Identification of two related pentapeptides from the brain with potent opiate agonist activityNature, 1975
- Primary Structure of Somatostatin, A Hypothalamic Peptide That Inhibits the Secretion of Pituitary Growth HormoneProceedings of the National Academy of Sciences, 1973
- Evidence for Calcitonin—A New Hormone from the Parathyroid That Lowers Blood CalciumEndocrinology, 1962